Fundraising Fox
Glycomine
San Francisco, US · Founded 2014 · 26 employees on LinkedIn · 12 known investors
Find your way into Glycomine
Each arrow is one introduction. Sign up to fill in the first one.
Ask Walter Olesiak to introduce you to Geoffrey Hird
You →Walter · together at Glycomine →Geoffrey
Ask Jamie Chen to introduce you to Steven Axon
You →Jamie · together at Complement Therapeutics →Steven
Ask Sam Okafor to introduce you to Hicham Alaoui
You →Sam · together at NeoGenesis Pharmaceuticals →Hicham
- Peter McWilliams12 people can intro you
Sign up to find every way you can get introduced to Glycomine
- Your email: who you already know at Glycomine, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Glycomine team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Founders & leadership
Glycomine was founded in 2014 by Agnes Rafalko.
Board
Investors · 12
How we know: Advent Life Sciences's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: Chiesi Ventures's portfolio page · board seat on SEC Form D · funding news · Not right? Tell us
How we know: CTI Life Sciences Fund L.P.'s portfolio page · funding news · Not right? Tell us
How we know: Mission Biocapital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
How we know: Remiges Ventures, Inc.'s portfolio page · funding news · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: Sanderling Ventures's portfolio page · funding news · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$234.9M disclosed across 3 of 5 rounds · 2016–2025
▶$4.9MraisedNov 2016 · 15 investors · BiotechnologyRule 506(b)
- Christopher StarrDirector
- Peter C.M. McWilliamsDirector
- Agnes RafalkoExecutive Officer, Director
- Giacomo ChiesiDirector
- Offering amount
- $12.6M
- Amount sold
- $4.9M
- Minimum investment
- $10K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Glycomine.
Frequently asked questions
- What does Glycomine do?
- Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
- Who founded Glycomine?
- Glycomine was founded by Agnes Rafalko in 2014.
- Who are Glycomine's investors?
- Glycomine's investors include Advent Life Sciences, Chiesi Ventures, CTI Life Sciences Fund L.P., Mission Bay Capital, Mission Biocapital, Remiges Ventures, Inc., RiverVest Venture Partners, Sanderling Ventures and 4 more.
- How much funding has Glycomine raised?
- Glycomine has disclosed $234.9M raised across 3 of its 5 known rounds.
- Where is Glycomine headquartered?
- Glycomine is headquartered in San Francisco, US.